先进治疗药物的创新与竞争。
Innovation and competition in advanced therapy medicinal products.
机构信息
Chapman University School of Pharmacy, Irvine, CA, USA.
Director of the Medication Outcomes Center, School of Pharmacy, University of California, San Francisco, CA, USA.
出版信息
EMBO Mol Med. 2019 Mar;11(3). doi: 10.15252/emmm.201809992.
Abstract
Advanced therapy medicinal products (ATMPs), including gene therapy, cell therapy and tissue engineering products, represent a paradigm shift in health care, but they are expensive. E. Seoane‐Vazquez, V. Shukla and R. Rodriguez‐Monguio discuss ATMPs prospects for the generics market.[Image: see text]
摘要
先进治疗药物产品（ATMPs），包括基因治疗、细胞治疗和组织工程产品，代表了医疗保健的范式转变，但它们非常昂贵。E. Seoane-Vazquez、V. Shukla 和 R. Rodriguez-Monguio 讨论了 ATMPs 对仿制药市场的前景。[图片：见正文]
相似文献
1
Innovation and competition in advanced therapy medicinal products.先进治疗药物的创新与竞争。
EMBO Mol Med. 2019 Mar;11(3). doi: 10.15252/emmm.201809992.
2
The evolution of nonclinical regulatory science: advanced therapy medicinal products as a paradigm.非临床监管科学的演变：以高级治疗药品为例
Mol Ther. 2013 Sep;21(9):1644-8. doi: 10.1038/mt.2013.175.
3
Clinical success of complex biological therapies: be careful what you wish for..复杂生物疗法的临床成功：愿望需谨慎。
Mol Ther. 2010 Oct;18(10):1737-8. doi: 10.1038/mt.2010.204.
4
United States Food and Drug Administration Regulation of Gene and Cell Therapies.美国食品药品监督管理局对基因和细胞疗法的监管
Adv Exp Med Biol. 2015;871:1-29. doi: 10.1007/978-3-319-18618-4_1.
5
Hospital Exemption for Advanced Therapy Medicinal Products: Issue in Application in the European Union Member States.高级治疗用医药产品的医院豁免：欧盟成员国的应用问题
Curr Stem Cell Res Ther. 2017;12(1):45-51. doi: 10.2174/1574888x11666160714114854.
6
Considerations for Cell and Gene Therapy Programs Entering the Clinical Space.考虑进入临床领域的细胞和基因治疗计划。
Clin Pharmacol Ther. 2023 Sep;114(3):569-577. doi: 10.1002/cpt.2971. Epub 2023 Jun 25.
7
Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon.美国食品和药物管理局对细胞和基因治疗产品的监管现状：即将出现的潜在疗法。
Cytotherapy. 2019 Jul;21(7):699-724. doi: 10.1016/j.jcyt.2019.04.002. Epub 2019 Jun 10.
8
Fecal transplantation poses dilemma for FDA.粪便移植给美国食品药品监督管理局带来了难题。
Nat Biotechnol. 2014 May;32(5):401-2. doi: 10.1038/nbt0514-401.
9
Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare.先进治疗药物产品和健康技术评估——基于价值和可持续医疗保健的原则和实践。
Eur J Health Econ. 2019 Apr;20(3):427-438. doi: 10.1007/s10198-018-1007-x. Epub 2018 Sep 18.
10
The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost.细胞和基因治疗产品概况：授权、终止与成本
Hum Gene Ther Clin Dev. 2019 Sep;30(3):102-113. doi: 10.1089/humc.2018.201. Epub 2019 Jul 16.
引用本文的文献
1
Pharmacoeconomic Profiles of Advanced Therapy Medicinal Products in Rare Diseases: A Systematic Review.罕见病中先进治疗药物的药物经济学概况：一项系统综述。
Healthcare (Basel). 2025 Aug 2;13(15):1894. doi: 10.3390/healthcare13151894.
2
Enhancing the clinical translation of stem cell models by focusing on standardization and international regulatory cooperation.通过专注于标准化和国际监管合作来加强干细胞模型的临床转化。
World J Stem Cells. 2025 Apr 26;17(4):102788. doi: 10.4252/wjsc.v17.i4.102788.
3
Gums as Macromolecular Crowding Agents in Human Skin Fibroblast Cultures.牙龈作为人皮肤成纤维细胞培养中的大分子拥挤剂
Life (Basel). 2024 Mar 25;14(4):435. doi: 10.3390/life14040435.
4
Macromolecular crowding in human tenocyte and skin fibroblast cultures: A comparative analysis.人肌腱细胞和皮肤成纤维细胞培养中的大分子拥挤：一项比较分析。
Mater Today Bio. 2024 Jan 28;25:100977. doi: 10.1016/j.mtbio.2024.100977. eCollection 2024 Apr.
5
Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries.20个国家的先进治疗药品定价与报销机制
Front Pharmacol. 2023 Nov 28;14:1199500. doi: 10.3389/fphar.2023.1199500. eCollection 2023.
6
Design of cell expansion processes for adherent-growing cells with mDoE-workflow.采用多变量实验设计工作流程的贴壁生长细胞的细胞扩增过程设计
Eng Life Sci. 2023 Apr 25;23(5):e2200059. doi: 10.1002/elsc.202200059. eCollection 2023 May.
7
Non-destructive classification of unlabeled cells: Combining an automated benchtop magnetic resonance scanner and artificial intelligence.非破坏性无标记细胞分类：结合自动化台式磁共振扫描仪和人工智能。
PLoS Comput Biol. 2023 Feb 21;19(2):e1010842. doi: 10.1371/journal.pcbi.1010842. eCollection 2023 Feb.
8
ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing.学术界的先进疗法医学产品（ATMP）开发与临床前药品生产质量管理规范（pre-GMP）环境：早期细胞和基因疗法开发与制造的安全保障
Immunooncol Technol. 2022 Oct 6;16:100099. doi: 10.1016/j.iotech.2022.100099. eCollection 2022 Dec.
9
Developmentally engineered bio-assemblies releasing neurotrophic exosomes guide in situ neuroplasticity following spinal cord injury.经发育工程改造的释放神经营养外泌体的生物组件可引导脊髓损伤后的原位神经可塑性。
Mater Today Bio. 2022 Aug 24;16:100406. doi: 10.1016/j.mtbio.2022.100406. eCollection 2022 Dec.
10
The Randomised Controlled Trial at the Intersection of Research Ethics and Innovation.研究伦理与创新交叉点的随机对照试验。
Pharmaceut Med. 2022 Oct;36(5):287-293. doi: 10.1007/s40290-022-00438-8. Epub 2022 Jul 25.
本文引用的文献
1
Biosimilar Cost Savings in the United States: Initial Experience and Future Potential.美国生物类似药的成本节约：初步经验与未来潜力
Rand Health Q. 2018 Mar 30;7(4):3. eCollection 2018 Mar.
2
Regulatory Considerations for Gene Therapy Products in the US, EU, and Japan.美国、欧盟和日本基因治疗产品的监管考量
Yale J Biol Med. 2017 Dec 19;90(4):683-693. eCollection 2017 Dec.
3
Cells as advanced therapeutics: State-of-the-art, challenges, and opportunities in large scale biomanufacturing of high-quality cells for adoptive immunotherapies.细胞作为先进的治疗方法：用于过继免疫疗法的高质量细胞的大规模生物制造的最新技术、挑战和机遇。
Adv Drug Deliv Rev. 2017 May 15;114:222-239. doi: 10.1016/j.addr.2017.06.005. Epub 2017 Jun 15.
4
Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?及时获取罕见病药物的伦理要求：能否协调经济激励与患者健康需求？
Orphanet J Rare Dis. 2017 Jan 5;12(1):1. doi: 10.1186/s13023-016-0551-7.
5
Bioequivalence: the regulatory career of a pharmaceutical concept.生物等效性：一个药学概念的监管历程。
Bull Hist Med. 2011 Spring;85(1):93-131. doi: 10.1353/bhm.2011.0024.
Zotero 插件